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ABSTRACT
Recent evidence indicates a link between Parkin-
son’s Disease (PD) and the expression of a-synuclein
(SNCA) isoforms with different 3′ untranslated re-
gions (3′UTRs). Yet, the post-transcriptional mech-
anisms regulating SNCA expression are unknown.
Using a large-scale in vitro /in silico screening we
identified RNA-binding proteins (RBPs) that inter-
act with SNCA 3′ UTRs. We identified two RBPs,
ELAVL1 and TIAR, that bind with high affinity to the
most abundant and translationally active 3′ UTR iso-
form (575 nt). Knockdown and overexpression ex-
periments indicate that both ELAVL1 and TIAR posi-
tively regulate endogenous SNCA in vivo. The mech-
anism of regulation implies mRNA stabilization as
well as enhancement of translation in the case of
TIAR. We observed significant alteration of both TIAR
and ELAVL1 expression in motor cortex of post-
mortem brain donors and primary cultured fibroblast
from patients affected by PD and Multiple System
Atrophy (MSA). Moreover, trans expression quanti-
tative trait loci (trans-eQTLs) analysis revealed that
a group of single nucleotide polymorphisms (SNPs)
in TIAR genomic locus influences SNCA expression
in two different brain areas, nucleus accumbens and
hippocampus. Our study sheds light on the 3′ UTR-
mediated regulation of SNCA and its link with PD
pathogenesis, thus opening up new avenues for in-
vestigation of post-transcriptional mechanisms in
neurodegeneration.
INTRODUCTION
Parkinson’s disease (PD) is the second most common hu-
man neurodegenerative disorder, after Alzheimer disease.
PD is a multifactorial disorder in which different factors
such as aging, genetic susceptibility and environmental in-
sults converge to cause neurodegeneration. Idiopathic PD
represents over 90% of PD cases, while genetic PD, caused
by mutations in one or more of the PD-associated loci, is
only 10% of the cases (1).
PD initiates in the central nervous system and spreads
to the peripheral and enteric parts of the nervous system.
The most important feature in the brains of PD patients is
the selective loss of dopaminergic pigmented neuronswithin
the substantia nigra and, to a lesser extent, neurons resid-
ing in the ventral tegmental and retrorubral areas (2). The
neuropathological hallmark of Parkinson’s disease is the
presence of eosinophilic inclusion in the soma of neurons
known as Lewy bodies (LBs), as well as in the neurites
where the inclusions are called Lewy neurites. LBs are com-
posed of a mixture of lipids, neuromelanin and up to sev-
eral hundred individual proteins, including ubiquitin, heat-
shock proteins, dj-1, sod1 and 2, synphilin-1, tau, tyrosine
hydroxylase, and many others, but the key component is
-synuclein (SNCA gene), a small protein enriched at the
presynaptic terminals (3).
The post-transcriptional mechanisms controlling SNCA
expression are at present unknown, although we previ-
ously observed that UTR-mediated regulation could play a
key role in controlling -synuclein protein abundance (4).
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Specific SNCA transcript isoforms with different 3′UTR
lengths have been found enriched in cerebral cortex sam-
ples of post-mortem PD patients (5). Recently, in a cohort of
202 cases of de novo motor PD, significantly lower levels of
SNCAmRNA with extended 3′UTRs have been quantified
by digital expression analysis (6). These findings are partic-
ularly relevant to PD etiopathogenesis: a switch of alterna-
tive polyadenylation to favour expression of specific SNCA
3′UTR isoforms enables the binding of a number of trans-
acting factors that alter protein production, localisation and
function.
Post-transcriptional networks induce changes in expres-
sion levels that are about one order of magnitude smaller
than those caused by transcription factors, but -synuclein
is highly concentrated at the pre-synaptic terminals of neu-
rons (70–140 uM) and even small fluctuations of its con-
centration can indeed induce aggregation (7). In the present
work we address the question of which RNA-binding pro-
teins (RBPs) are able to bind the different 3′UTRs of SNCA
mRNA and control its expression. Following the unbiased
discovery of protein interactors by means of a large-scale in
vitro / in silico screening, we prioritised twoRBPs, ELAVL1
and TIAR, that target SNCA 3′UTRs and their influence
stability and translation efficiency. Our study suggests that
TIAR and ELAVL1 are key regulators of -synuclein intra-
cellular concentration and function.
MATERIALS AND METHODS
Human protein array
The RNA sequence corresponding to SNCA 3′UTR short
(575 bp), medium (1.07 kb) and long (2.5 kb) were cloned
in pBluescript-SK(+) empty plasmid. The RNA probes of
the SNCA long 3′UTR (3′UTRL) were synthesized by in
vitro transcription (IVT) with T7 and T3 RNA polymerase
(Agilent) for the sense and antisense strand respectively,
and fluorescently labeled with Label IT Array Cy5 label-
ing kit (Mirus) applying minor modifications to manufac-
turer’s instructions. RNA concentration and labeling den-
sity were measured with Nanodrop 1000 spectrophotome-
ter (Thermo Scientific). RNA integrity was verified by Ag-
ilent 2100 Bioanalyzer. The two probes corresponding to
the SNCA 3′UTR long sense and antisense sequence were
loaded on a 1% agarose denaturing gel (2.2 M formalde-
hyde). Both the size and the integrity of the probes were
checked.
ProtoArray® Human Protein Microarrays v5.2 (Life
Technologies), containing 9546 spotted proteins, were
probed with the Cy5 labeled RNA of interest as previously
reported (8). The dry slides were scanned within 2 h of the
completion of the hybridization using aGenePix 4000BMi-
croarray scanner (Molecular Devices). The intensity of the
signal at 635 nmwavelength at each spotted protein location
was determined with GenePix Pro 6.1 software (Molecular
Devices). Data was filtered based on signal to background
ratio for each of the duplicate spots to be >2.5-fold and Z-
score ≥ 3 from the global mean signal from all the spotted
proteins.
Luciferase gene reporter assay
SNCA short 3′UTR (570 bp), medium (1.07 kb) and long
(2.5 kb) were sub-cloned in a pGL4-TK-Firefly luciferase
(pGL4-TK-FL) plasmid vector at the 3′end of the Firefly
luciferase coding sequence. To guarantee the expression of
the long or medium 3′UTR isoforms only, the proximal
polyadenylation sites (PAS), present within the sequence of
the 3′UTRs, were deleted at positions 262–267 nt, 468–473
nt, 529–553 nt and 1054–1059 nt (taken from (9)).
HeLa cells at 80% of confluency were transfected with
with Lipofectamine 2000 (Life Technologies) following
manufacturer’s instructions. 130 fmol of pGL4-TK-FL
empty plasmid or pGL4-TK-FL carrying the sequence of
the short medium or long 3′UTR, were co-transfected with
50 ng of pGL4-TK-Renilla luciferase plasmid (pGL4-TK-
RL), used as internal control to normalize for differences in
transfection efficiency.
Forty eight hours after transfection, the dual lu-
ciferase activity was measured at a Tecan Infinite M-200
plate reader, using Dual-Luciferase reporter assay system
(Promega) following manufacturer’s instructions. Firefly lu-
ciferase activity was normalized with Renilla luciferase ac-
tivity and then normalized Firefly luciferase activity of
pGL4-TK-FL-SNCA 3′UTRs constructs was compared to
the activity of pGL4-TK-FL vector.
In the case of TIAR and ELAVL1 knock-downs, the
RNA corresponding to each of the aforementioned con-
structs were in vitro transcribed usingMEGAscript T7 tran-
scription kit (Ambion) in presence of modified G-cap nu-
cleotide. HeLa control and knockdown cells were seeded
in 48-well plates and Firefly and Renilla RNA were co-
transfected using TransMessenger transfection reagent (QI-
Agen) following manufacture’s instructions. Four hours af-
ter transfection cells were lysed and the dual luciferase ac-
tivity was measured as described before.
RNA affinity purification
The biotinylated RNA probes of SNCA short 3′UTR
(3′UTRS) and long (3′UTRL) were synthesized by in vitro
transcription from linearized pBSK plasmid vector by us-
ing a T7 MegaScript kit (Ambion) with addition of biotin-
14-CTP (Life Technologies). RNA concentration and in-
tegrity were verified by NanoDrop 1000 spectrophotome-
ter (Thermo Scientific) and by denaturing agarose gel
electrophoresis of the RNA. Successful biotinylation was
checked using the Chemiluminescent Nucleic Acid Detec-
tion Module kit (Thermo Scientific).
RNA affinity purification was performed as described by
Hammerle M. with some adaptations (10) (see Supplemen-
tary Materials for details).
RNA electrophoretic mobility shift assay
Fragments A (1–192 nt), B (193–390 nt) and C (391–
575 nt) of SNCA 3′UTR short were obtained by deletion
of pBSK(+)-3′UTR short with Gibson cloning approach.
Corresponding radiolabeled RNA probes were synthesized
by IVTwithT7Megascript kit (Ambion) and incorporation
of 32P-UTP (Perkin Elmer). Size and integrity of the probe
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were verified on a 8% TBE-Urea gel, while probe radioac-
tivity was measured with a scintillation counter (Perkin
Elmer). N-terminal GST-tagged TIAR and ELAVL1 pro-
teins were overexpressed in Escherichia coli from pGEX2T
and pDEST15 vectors, respectively, and purified using glu-
tathione sepharose beads. The RNA electrophoretic mobil-
ity shift assay and the competition assay were performed as
previously described (11) (see Supplementary Materials for
details).
RNA stability assay
Hela cells (control, TIAR and ELAVL1 knockdown) were
seeded in 12-wells plate at a density of 1.6 × 105 cells per
well. The general transcription inhibitor actinomycin D
(Sigma Aldrich) was added at a concentration of 5 g/ml for
0, 4, 8 and 12 h. Total RNA was isolated with Maxwell 16
LEV simply RNA cells kit (Promega) and analyzed by RT-
qPCR. ACTB was used as a reference gene for normaliza-
tion (Ct), and the Ct of each time point was compared
to time 0 h (Ct). For each experiment the average of trip-
licate wells per condition was calculated and used to deter-
mine mean values and standard deviation of three biologi-
cal replicates. A Student’s t-test was performed to assess for
significant differences of RNA decay rate between the three
conditions.
Measurement of -synuclein, TIAR and ELAVL1 levels in
motor cortex and primary fibroblasts of Parkinson’s disease
(PD) and Multiple System Atrophy (MSA) patients
The human post-mortem motor cortex brain tissue stored
at –80◦C was obtained from the Brainbank from In-
stitut d’Investigacions Biome`diques August Pi I Sunyer
(IDIBAPS)-Biobank, with the corresponding informed
consent signed by donors or relatives. Approval of the local
ethics committee was requested for the use of brain tissue
and for access tomedical records for research purposes. The
tissue samples were dissected and used in a manner com-
pliant with the Declaration of Helsinki. Brain tissue of five
Parkinson’s disease (PD) patients, five Multiple System At-
rophy (MSA) patients and four control individuals (without
neurological affectation) was used in this study. The three
groups were matched for age of onset and age of death, gen-
der and severity of the disease (Supplementary Table S1).
Primary cultured fibroblasts (∼5 million cells/pellet)
were obtained from skin biopsy of idiopathic PD, LRRK2-
associated PD, MSA patients and healthy control individu-
als (Supplementary Table S2).
Total proteins were extracted by lysing with RIPA buffer
supplemented with Protease inhibitors (Roche). After soni-
cation with bioruptor sonifier (Branson) samples were cen-
trifuged at 16 000 g for 15 min and supernatants were mea-
sured with Bradford reagent (Sigma Aldrich). -synuclein,
TIAR, ELAVL1, tubulin and -actin levels were measured
by western blot as described previously. Statistical signifi-
cance was calculated by Wilcoxon’s test.
RNA 3′end sequencing, polysome profiling, TIAR and
ELAVL1 knockdown and overxpression
See SupplementaryMaterials for detailed description of the
protocol.
RESULTS
Large-scale identification of 3′ UTR interactions
Human SNCA mRNA is expressed with five isoforms of
different 3′UTR lengths (ranging from 290 nt to 2500 nt)
depending on the choice of the polyadenylation site (5).
We probed the largest SNCA 3′UTR (2500 nt, contain-
ing sequences of the other isoforms, Figure 1A) and its an-
tisense RNA (negative control) on three separate protein
arrays (8,12) obtaining high reproducibility between repli-
cates (Pearson’s correlations of >0.90; Figure 1B and C;
Material andMethods; SupplementaryMaterials). To iden-
tify significant binding events, we selected proteins with fold
change (signal to background ratio) >2.5 and associated
Z-score >3, obtaining around 100 proteins per experiment
(8,12). By considering the intersection of three independent
replicates, and removing interactions in common between
sense and antisense RNAs, we discarded unspecific binders.
Out of 9546 candidates, we identified 27 proteins binding to
SNCA 3′UTRs (Figure 1D).
Following a recently published approach (13), we used
the catRAPID algorithm (14) to prioritize candidates
for experimental characterization (Supplementary Materi-
als). catRAPID estimates RNA–RBP affinities exploiting
physico-chemical properties of nucleotide and amino acid
chains including secondary structure, hydrogen bonding,
and van der Waals’ propensities to predict protein–RNA
associations (15). Importantly, catRAPID calculations of
RBP interactions with SNCA 3′UTR show high agreement
with protein array results (strong signal RBPs are predicted
with an Area under the ROC curve >0.80; Supplementary
Materials; Supplementary Figure S1A).
Our approach indicates that TIAR,CELF1 andELAVL1
have the highest interaction propensities (catRAPID in-
teraction score > 2; Figure 1D). We selected TIAR and
ELAVL1 for a more in depth investigation as they are sig-
nificantly down-regulated in PD patients (differently from
CELF1; Figure 1E) (16).Moreover, literature evidence indi-
cates that TIARandELAVL1bind to similar sequences and
regulate mRNA stability and translation (17–22), thus sug-
gesting common mechanisms of action on SNCA 3′UTR.
Comparison of our RBP candidates with interactions re-
ported in the UTR database AURA (23,24) reveals that
TIAR and ELAVL1 have the largest number of binding
sites in SNCA 3′UTR (respectively: 6 for TIAR and 12 for
ELAVL1), while other proteins are associated with lower
signal intensities (AGO1; catRAPID score = 1.39; 1 bind-
ing site) or interact with control RNA (TIA1; catRAPID
score = 2.46; 4 binding sites; Supplementary Figure S1B).
SNCA with short 3′UTR is predominant in SH-SY5Y and
HeLa cells and has increased protein translation
To quantify the abundance of the different 3′UTR isoforms
of SNCAmRNA (Figure 2A), we performed a modified se-
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Figure 1. Large scale screening of SNCA 3′UTR protein interactors. (A) SNCA 3′UTR long (3′UTR L) used in our experiments in vitro; Pearson’s cor-
relation between two protein array replicates probed with (A) 3′UTR L sense and (B) antisense (right) RNAs. (sense: R = 0.89; (C) antisense: R = 0.93).
Selected binders with fold change (signal to background ratio) >2.5 and associated Z-score > 3 are represented as red dots, while less significant binders
are reported in grey. (D) Median value of catRAPID score of SNCA 3′UTR top interactors: 27 proteins; TIAR (also known as TIAL1) and ELAVL1
(ELAV1) are highlighted in red). (E) Sketch of the in vitro / in silico procedure followed to identify TIAR and ELAVL1 interactions.
quencing protocol to which we refer as gene specific-3′end
RNA sequencing (Material and Methods; Supplementary
Materials).
We used two different cell lines, HeLa and human neu-
roblastoma cells (SH-SY5Y). SH-SY5Y cells were in vitro
differentiated towards a dopaminergic neuron-like phe-
notype by treatment with retinoic acid (RA) and 12-O-
tetradecanoyl-phorbol-13-acetate (TPA), in order to reca-
pitulate the biological context of substantia nigra dopamin-
ergic neurons that are mainly affected in Parkinson’s disease
(25).We found that the isoform carrying the 575 nt 3′UTR is
the most abundant accounting for 51.5% and 41.3% of total
SNCAmRNA inHeLa and in vitro differentiated SH-SY5Y
respectively (Figure 2B). The least abundant isoforms cor-
respond to those carrying 480 nt and 2.5 kb long 3′UTR
(Figure 2B). The isoform carrying the 2.5 kb long 3′UTR is
instead expressed 2.5 times more in SH-SY5Y than HeLa
cells, in agreementwith the lengthening of 3′UTRs observed
in the brain (Figure 2B) (26).
Moreover, the relative firefly luciferase activity of con-
struct FL-SNCA 3UTRS (575 nt) was more than 3.5 and
17.5 times higher than the firefly luciferase empty vector
andFL-SNCA3UTRL (2.5 kb) respectively (Figure 2C and
D; P-value < 0.05; Wilcoxon test). A similar trend is ob-
12892 Nucleic Acids Research, 2017, Vol. 45, No. 22
CDS 5’UTR 3’UTR 
2530 nt  
nt1074  
nt575  
nt480  
290 nt 
29
0 n
t
48
0 n
t
57
5 n
t
10
74
 nt
25
30
 nt
0
20
40
60
3'UTR length (nt)
%
 S
N
C
A
-3
'U
TR
 is
of
or
m H e La
S H -S Y 5 Y  R A+ TP A
575 nt
1074 nt
2530 nt
TK FLuc
TK FLuc 3UTRM
TK FLuc 3UTRL
TK FLuc
pGL4-TK-Fluc
5’ 3’
5’ 3’
5’ 3’
5’ 3’
3UTRS
FL
FL
-S
NC
A 
3U
TR
S
FL
-S
NC
A 
3U
TR
M
FL
-S
NC
A 
3U
TR
L
0
1
2
3
4
5
FL
 re
la
tiv
e 
lig
ht
 u
n i
ts
 (R
U
) **
**
**
A
B
C
D
Figure 2. Measurement of SNCA 3′UTR isoforms expression in HeLa and in vitro differentiated SH-SY5Y cell lines and effect of 3′UTR length on gene
reporter activity. (A) Details of the five isoforms of SNCA transcript with different lengths of the 3′UTR, ranging from 290 nt (light green) to 2.5 kb (red).
(B) Percentage of each of the five SNCA transcript isoforms in HeLa cells and in vitro differentiated SH-SY5Y cells measured by gene-specific 3′end RNA
sequencing. (C) Dual luciferase gene reporter assay. Scheme of the three constructs carrying the sequence of SNCA 3′UTR S (575 nt), M (1074 nt) and L
(2530 nt) at the 3′ of luciferase coding sequence. (D) Firefly relative to Renilla luciferase activity of the three constructs (FL-SNCA 3′UTRS, FL-SNCA
3′UTRM and FL-SNCA 3′UTRL) compared to control empty vector FL. * P-value < 0.05 (Wilcoxon’s test).
served at the RNA level, with FL-SNCA 3UTRS being two
times more abundant than the control vector carrying only
the luciferase coding sequence (Supplementary Figure S2).
Our finding suggests that the long 3′UTR contains a higher
number of sequence elements targeted by trans-acting fac-
tors, such as microRNAs and destabilizing RBPs, which
promote RNA degradation or inhibit its translation.
Taken together, our experiments indicate that the isoform
carrying the short 3′UTR is mostly contributing to protein
production and we proceeded to further characterise TIAR
and ELAVL1 binding and their action.
TIARandELAVL1 are able to bind specific regions ofSNCA
3′UTR in vitro and in vivo
Using an RNA affinity purification assay we confirmed that
TIAR and ELAVL1 bind to both SNCA ‘long’ (2.5 kb) and
‘short’ (575 nt) 3′UTR isoforms (Figure 3A; Material and
Methods; Supplementary Materials).
As shown in Figure 3B–D, ELAVL1 interacts preferably
with the long 3′UTR, in agreement with previously pub-
lished CLIP data that report the presence of multiple bind-
ing sites all along the 2.5 kb of the 3′UTR (27–29) (Fig-
ure 3A). TIAR interacts with both 3′UTRs (Figure 3B and
C) in accordance with CLIP binding sites mapped in the
first 600 nt of the UTR region (30) (Figure 3A). FMR1
was chosen as a negative control on the basis of protein mi-
croarray results (fold change < 1.7). As shown in Figure
3B, FMR1 does not bind to the two RNA sequences tested.
TIAR and ELAVL1 binding was also confirmed in absence
of UV cross-linking (Supplementary Figure S3).
We next defined the region of SNCA short 3′UTR (575
nt) that interacts with TIAR and ELAVL1 by measur-
ing electrophoretic mobility of nucleotides 1–192 (A), 193–
390 (B) and 391–575 (C; Figure 4A) upon incubation with
increasing concentrations of the GST-tagged TIAR and
ELAVL1 proteins (Figure 4B and C). As shown in Figure
4B and C, both proteins have a binding ability to the three
fragments but the highest affinitywas observed for fragment
B (Supplementary Figure S5). Indeed, TIAR and ELAVL1
bind specifically to fragment B, as seen by using fragments
A, B and C as unlabeled competitors (Figure 4D and E).
We also observed higher molecular complexes in the case of
ELAVL1, corresponding to dimers and multimers forming
upon incubationwith high ELAVL1 concentrations (Figure
4C). To further investigate TIAR and ELAVL1 binding to
fragment B, we incubated the RNA with a fixed amount of
one protein and increasing amounts of the other. As shown
in Figure 4F, the two proteins compete for their binding to
fragment B and increasing amounts of TIAR or ELAVL1
show clear displacement of the protein/RNA complex.
These experiments indicate that nucleotides 193–390
(fragment B) interact with TIAR and ELAVL1 proteins
with the highest binding affinity and sequence specificity
and that the two proteins compete for the binding.
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Figure 3. In vitro validation of TIAR and ELAVL1 binding to SNCA 3′UTR. (A) CLIP binding sites along the sequence of SNCA 3′ UTR as reported in
the Atlas of UTR regulatory activity (AURA) database (http://aura.science.unitn.it/). TIAR cluster of binding sites (291–318, 353–367, 429–437, 476–511,
578–584 nt) are represented as pink boxes and ELAVL1 binding sites (230–315, 1224–1276, 1546–1567, 1650–1690, 2057–2102, 2113–2153 and 2229–2269
nt) are represented as blue boxes. (B) RNA affinity purification assay performed in technical triplicates. (C) TIAR and (D) ELAVL1 are co-purified with
the in vitro synthesized RNA of SNCA 3′UTR long and short (Western Blot). FMR1 is used as negative control.
Post-transcriptional regulation of SNCA by TIAR and
ELAVL1
TIAR and ELAVL1 knockdown and overexpression in
HeLa cells indicate that the two RBPs play a positive reg-
ulatory role on SNCA expression (Material and Methods;
Supplementary Materials). This is particularly evident in
the case of TIAR whose expression significantly influences
the levels of both SNCA RNA and protein (Figure 5A–
C, Figure 5G–I) inducing changes in expression that are
compatible with those observed in idiopathic Parkinsonism
(31,32). More specifically, upon TIAR knockdown we ob-
served a significant decrease of endogenous -synuclein ex-
pression at the RNA and protein level with a 0.63 and 0.5
fold-change respectively (Student’s t-test, P-value < 0.01,
Figure 5A–C). TIAR overexpression induces a 2.2 and 1.6
fold increase in -synuclein RNA and protein, respectively.
By contrast, ELAVL1 showed amilder effect andmainly on
SNCA protein levels (Figure 5D–F, Figure 5J–L). Indeed,
upon ELAVL1 knockdown we observed∼0.8-fold decrease
of-synucleinRNAandprotein levels, while ELAVL1over-
expression only increases the protein levels of 1.52-fold with
no significant change of the mRNA levels with respect to
control.
The decrease of SNCA mRNA upon knockdown of
TIAR and, to a lesser extent, of ELAVL1, suggest that
one of the possible mechanisms of regulation orchestrated
by these proteins could be the stabilisation of the mRNA
through direct binding at the 3′UTR and interference with
RNA degradation factors such as microRNAs and other
RBPs. As a matter of fact, the role of ELAVL1 as an RNA
stabilizing factor is extensively documented in the literature
(33,34). In the case of TIAR, the protein is also known for
its effect on translation regulation (35–37) but we cannot ex-
clude that the protein might play other functions in mRNA
metabolism.
We used the transcription inhibitor actinomycin D to
test that the two proteins could stabilize SNCA mRNA.
We measured a decay rate of 30% and 43% in TIAR and
ELAVL1 knockdown cells respectively while only 5% decay
rate was observed in control cells at 4 hours of actinomycin
D treatment (Figure 6A and B), showing that both RBPs
protect SNCA mRNA from degradation.
As TIAR and ELAVL1 are reported to modulate mRNA
translation (35–37), we decided to test whether they could
participate to the translation of SNCA mRNA. To do so,
we traced the distribution of SNCA mRNA across dif-
ferent fractions of the polysome profile of HeLa control,
TIAR and ELAVL1 knockdown cells (Figure 6C). In all
three conditions SNCA mRNA was distributed (70–75%)
between fractions 3 and 7 or more (10–12,38) ribosomes.
We observed a substantial shift of SNCA mRNA in cells
depleted for TIAR protein, from the more translationally
active high molecular weight (HMW) polysomal fraction
12, corresponding to six-seven ribosomes, to the less trans-
lationally active low molecular weight (LMW) fraction 10,
which corresponds to three ribosomes (Figure 6D). Indeed,
only 12.9% of SNCA mRNA co-sedimented with fraction
12 in TIAR knockdown cells compared to 27.5% of SNCA
mRNA present in the same fraction in control cells. In con-
trast, no relevant change was observed upon knockdown of
ELAVL1 (Figure 6D).
We conclude that, in addition to stabilizing SNCA
mRNA, TIAR also promotes SNCA mRNA translation
through a mechanism that needs to be further elucidated.
By contrast, ELAVL1 seems to play a main role in SNCA
mRNA stabilization, in agreement with its very well docu-
mented function in RNA metabolism. Yet, it does not have
any relevant effect on its translation efficiency.
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Figure 4. In vitro characterization of TIAR and ELAVL1 binding sites of SNCA 3′UTR short. (A) Schematic representation of the sequence of SNCA
3′UTR S and TIAR/ELAVL1 binding sites previously identified by CLIP. The sequence of the 3′UTR S is divided into three fragments (A, B and C) of
∼190 nt each to test the binding ability of TIAR and ELAVL1. (B) RNA electrophoretic mobility shift assay (REMSA) of fragments A, B and C of SNCA
3′UTR S upon incubation with increasing concentrations of GST-tagged TIAR protein (0, 100, 200, 500 nM). (C) RNA electrophoretic mobility shift
assay (REMSA) of fragments A, B and C of SNCA 3′UTR S upon incubation with increasing concentrations of GST-tagged ELAVL1 protein (0, 100,
200, 500 nM). (D) Competition gel shift assay showing binding specificity of TIAR protein for fragment B. Lane 1. Probe B alone, Lane 2. Probe B with
200 nM TIAR, Lane 3–11. Probe B with 200 nM TIAR in presence of 0.1, 1 and 10 nM of cold probe A, B and C. (E) Competition gel shift assay showing
binding specificity of ELAVL1 protein for fragment B RNA. Lane 1. Probe B alone, Lane 2. Probe B with 100 nM ELAVL1, Lane 3–11. Probe B with 100
nM ELAVL1 in presence of 0.1, 1 and 10 nM of cold probe A, B and C. (F) Competition assay. Labeled fragment B was incubated with 200 nM of TIAR
(lane 2) or 200 nM of ELAVL1 (lane 7). Competition between TIAR and ELAVL1 was performed by incubating fragment B with constant amount of
TIAR (200nM) and increasing amount of ELAVL1 (lanes 3, 4 and 5) or constant amount of ELAVL1 (200nM) and increasing amounts of TIAR (lanes
8, 9 and 10).
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Figure 5. Analysis of TIAR and ELAVL1 regulatory role on -synuclein expression in HeLa cells. (A) Relative SNCA mRNA levels measured by qPCR
upon stable knockdown of TIAR in HeLa cells compared to control cells. (B) -synuclein protein down-regulation measured by Western Blot upon stable
knockdown of TIAR protein in HeLa cells. (C) Average and standard deviation of seven biological replicates are reported (**P-value < 0.01, Student’s t-
test). (D) Fold change of SNCAmRNA upon KD of ELAVL1. (E) -synuclein protein down-regulation measured by western blot upon stable knockdown
of ELAVL1 in HeLa cells. (F) Average and standard deviation of seven biological replicates are reported (**P-value < 0.01, Student’s t-test) (G–I) Relative
SNCA mRNA and -synuclein protein up-regulation in HeLa cells overexpressing GFP-tagged TIAR protein compared to control cells (**P-value <
0.01, Student’s t-test). (J-L) Relative SNCAmRNA and -synuclein protein levels in HeLa cells overexpressing ELAVL1 protein compared to control cells
(*P-value < 0.05, Student’s t-test).
TIAR and ELAVL1 regulation is mediated by SNCA 3′UTR
To test whether the regulation observed endogenously (Fig-
ure 5) requires the binding to SNCA 3′UTRs, we mea-
sured the dual firefly luciferase activities of the constructs
FL-SNCA 3UTRS, FL-SNCA 3UTRM and FL-SNCA
3UTRL upon TIAR or ELAVL1 knockdown.We obtained
a significant decrease of the relative firefly luciferase activity
of 3′UTRS, 3′UTRM and 3′UTRL in HeLa cells depleted
of TIAR (Figure 7A). More specifically, we measured a
fold decrease of 0.63, 0.68 and 0.61 for FL-SNCA 3′UTRS,
FL-SNCA 3′UTRM and FL-SNCA 3′UTRL. No signif-
icant change was instead observed for the construct carry-
ing the sequence of the firefly luciferase gene, indicating that
the decrease is specific for the constructs containing SNCA
3′UTRs. Our result indicates that the positive regulatory
role of TIAR is indeed achieved through the direct binding
of the RBP to the 3′UTR of SNCA mRNA, in agreement
with our initial hypothesis. As for ELAVL1KD, only amild
decrease of the signal is observed in all three RNAs contain-
ing SNCA 3′UTRs with respect to control HeLa cells with
an average fold change of 0.86, 0.88 and 0.77 respectively
Figure 7B).
MicroRNAs do not compete with TIAR and ELAVL1 bind-
ing to SNCA 3′ UTR in HeLa cells
Previous reports indicate that ELAVL1 regulates mi-
croRNA expression by intervening in pri- or pre-
microRNAs processing of miR-7 and miR-16 (39,40).
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Figure 6. TIAR and ELAVL1 role in SNCA mRNA stability and translation. (A) Percentage of remaining SNCA mRNA measured at 0, 4, 8 and 12 h
after transcription inhibition with actinomycin D in control, TIAR knockdown and ELAVL1 knockdown HeLa cells. Mean and standard deviation of
three independent experiments are shown (Kolmogorov-Smirnov test with respect to control curve, *P-value < 0.1; **P-value < 0.01). (B) VEGF mRNA
is a control for the effectiveness of the actinomycin D treatment. (C) Polysome profile of HeLa control, TIAR knockdown and ELAVL1 knockdown cells.
(D) Percentage of SNCA mRNA distribution across polysome gradient in HeLa control, TIAR knockdown and ELAVL1 knockdown conditions. Data
shown are mean with standard deviation of three independent experiments.
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Figure 7. Dual firefly luciferase activity of SNCA 3′ UTRs upon TIAR or ELAVL1 knockdown. We measured luciferase activities of SNCA 3′UTRs with
respect to control empty vector FL. (A) TIAR KD. We observed a fold decrease of 0.63, 0.68 and 0.61 for FL-SNCA 3′UTRS, FL-SNCA 3′UTRM and
FL-SNCA 3′UTRL. No significant change was instead observed for the construct carrying the sequence of the firefly luciferase gene (B). ELAVL1 KD.
Mild decrease of the signal is observed for FL-SNCA 3′UTRS, FL-SNCA 3′UTRM and FL-SNCA 3′UTRL with an average fold change of 0.86, 0.88
and 0.77 respectively. * P-value < 0.05 (Wilcoxon’s test).
As miR-7 has been implicated in down-regulation of
SNCA expression (41), it is possible that a regulatory
loop involving ELAVL1 inhibition of miR-7 causes re-
lease of SNCA from miR-7 producing an increase of
-synuclein expression. Such a scenario is compatible with
our observation that ELAVL1 depletion induces SNCA
down-regulation, which could be mediated by miR-7 up-
regulation. However, when we measured miR-7 expression
in ELAVL1 in both knockdown and control HeLa cells, we
found that the general level of expression of miR-7 is very
low (PCR cycle threshold Ct of 33, while U6 control shows
Ct of 27) and we therefore ruled out its involvement.
Similarly, the overlap between TIAR binding site (Fig-
ure 3B-C) and the target region of miR-153, which was re-
ported to down-regulate SNCA expression (42), suggested
a possible competition between the two trans-factors. How-
ever, miR-153 expression is almost undetectable in HeLa
cells (PCR cycle threshold Ct of 33, while U6 control shows
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Ct of 22), therefore its participation in -synuclein down-
regulation upon TIAR depletion is very unlikely to occur
in our cellular system. Yet, we cannot exclude that miR-153
could play a role in TIAR regulation in the nervous system.
We then used the multiMiR algorithm (43) to systemati-
cally investigate other microRNAs interacting with the long
SNCA 3′UTR (containing all other 3′UTRs). We collected
a total of 142 predicted and 9 experimentally validated mi-
croRNAs (MultiMiR score > 0.7) and manually retrieved
their binding sites from themicroRNA.org server.Using the
PhastCons score to measure evolutionary conservation of
sequence blocks across multiple vertebrates (44), we sepa-
rated the microRNAs in two classes: conserved (PhastCons
score> 0.57 corresponding to conservation across all mam-
mals) and non-conserved (PhastCons score < 0.57).
We specifically focused on microRNAs having binding
sites overlapping with TIAR and ELAVL1 SNCA 3′UTR
contacts annotated in AURA database (23,24). We found
a total of 9 microRNAs co-localizing with ELAVL1 bind-
ing regions, but only one of them, miR-539–5p, was found
to be conserved. As for TIAR, two non-conserved microR-
NAs, miR-126–5p andmiR-3134, showed contacts overlap-
ping with the binding sites of the protein. We proceeded to
test the expression levels of the microRNAs in our HeLa
cells by means of a high throughput approach (Supple-
mentary Material). After signal normalization, we found
around 432 miRNAs that passed the expression threshold.
However, none of those miRNAs overlap with either TIAR
or ELAVL1 binding sites. In accordance with this result, an
external dataset taken from a published high-throughput
small RNA sequencing analysis (45) reveals nearly unde-
tectable levels of expression of candidate microRNAs (Sup-
plementary Table S3).
Overall, our analysis indicates that microRNAs levels of
expression are poor in two independent HeLa cell lines, as
also directly observed for miR-7 and miR-153 by TaqMan
assay. We therefore ruled out that these microRNAs might
have a role in TIAR- and ELAVL1-dependent SNCA regu-
lation in the cell model used for our functional assays.
TIAR and ELAVL1 expressions are altered in frontal motor
cortex and in primary fibroblasts from patients affected by
PD and MSA synucleinopathies
To address implications of TIAR or ELAVL1 in the onset
of neurodegeneration, we investigated whether their abun-
dances are altered in conditions associated with changes
in -synuclein expression: PD and another synucleinopa-
thy, Multiple System Atrophy (MSA). PD and MSA be-
long to a group of synucleinopathies characterized by ab-
normal accumulation of -synuclein. Differently from PD,
where -synuclein positive aggregates appear to be largely
neuronal, oligodendroglia inclusion prevail inMSA (46,47).
The pathogenic mechanisms leading to neurodegeneration
in MSA are not well understood, but partially differ from
PD since MSA patients show resistance to L-dopa treat-
ment (48,49). In contrast to PD, disease-causative genetic
mutations responsible of monogenic forms of MSA have
so far not been identified (50–52). Neurodegeneration typ-
ically occur with a multisystemic distribution that partially
differs from the one observed in PD. For this reason, we de-
cided to examine the frontalmotor cortex, which is generally
affected with similar degree in both PD andMSA at the late
stages (Supplementary Table S1; Material and Methods;
SupplementaryMaterials).We found that TIARwas down-
regulated in PD with respect to control individuals with a
fold-change of 0.65 (P-value= 0.09,Wilcoxon’s test, Figure
8A and B; four controls, five PD and five MSA cases). No
alteration of ELAVL1 expression was observed in PD, while
a 1.5-fold increase was measured in MSA when compared
to controls (P-value = 0.15, Wilcoxon’s test, Figure 8A–D).
The results correlated with -synuclein protein expression
that was found decreased in PD with respect to controls
(fold-change= 0.49,P-value= 0.15,Wilcoxon’s test, Figure
8A–C) and slightly increased in MSA. In agreement with
these results, Neystat et al. showed reduction of SNCA ex-
pression in substantia nigra of PD affected individuals (53)
and another group reported 50% reduction at the cellular
level in substantia nigra neurons and frontal cortex neurons
in PD (54). Also in accordance with our findings, oligoden-
drocytes isolated from MSA brains expressed elevated lev-
els of SNCA compared to control (55) and a recent strand-
specific RNA-sequencing analysis of MSA brain transcrip-
tome reported a moderate increase of SNCA expression in
frontal cortex of MSA patients compared to normal indi-
viduals (56).
Analysis of primary cultured fibroblast obtained from
human skin biopsies of sporadic PD (sPD), LRRK2-
associated PD (L2PD), MSA and healthy control individ-
uals (Supplementary Table S2) revealed that -synuclein
is also very poorly expressed in the tissue (Supplementary
Figure S6A). Nevertheless, we could measure a significant
down-regulation of TIAR in PD and MSA patients with
respect to control individuals (Supplementary Figure S6A-
B). Results were similar when the two PD groups (sPD
and L2PD) were analyzed together or separately (Supple-
mentary Figure S6B-D), with the exception of ELAVL1 for
which we observed a statistically significant increase specific
of the L2PD group (Supplementary Figure S6E).
Overall, our results show an alteration of TIAR and
ELAVL1 levels in two different tissues of patients affected
by PD or MSA. Due to intra-group variability and small
sample size we cannot exclude that the observed changes are
due to other causes. Nevertheless, TIAR down-regulation
is consistent in both tissues and is accompanied by -
synuclein decrease in motor cortex, in agreement with our
functional assays.
Trans-expression quantitative trait loci analysis reveals func-
tional association between TIAR and SNCA
To investigate if naturally occurring mutations in SNCA
RNA could affect ELAVL1 and TIAR binding, we down-
loaded all the single nucleotide polymorphisms (SNPs) an-
notated in 1000 Genomes (hg19) within the genomic coor-
dinate of the 3′UTR (4:90, 645, 249–90, 647, 778).
The SNPs were ranked using CADD (57) to select func-
tional and deleterious variants based on characteristics such
as evolutionary conservation, type of substitution and pres-
ence of regulatory elements. The degree of the deleterious-
ness of SNPs was measured using PHRED (score > 10 in-
dicates significant implication). Out of 67 SNPs, 5 SNPs fall
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Figure 8. TIAR, ELAVL1 and -synuclein protein levels in motor cortex post-mortem samples. (A) -synuclein TIAR and ELAVL1 protein level in motor
cortex tissue of post-mortem control individuals, PD andMSA patients measured by western blot. Normalized average values of (B) TIAR, (C) -synuclein
and (D) ELAVL1 in the three groups (Wilcoxon’s test P-values are reported).
into ELAVL1 binding sites, 3 in TIAR binding sites and 2
are located in ELAVL1/TIAR shared binding regions. 6 of
these SNPs overlapping with TIAR/ELAVL1 binding sites
have a PHRED score >10, suggesting possible effect on
SNCA expression and functionality (Supplementary Table
S4).
In addition, we investigated 6 SNPs associated to PD (58)
and found that one of them, rs356165, is located in SNCA
3′UTR. The other 5 SNPs are in a genomic region >20KB
downstream SNCA 3′UTR. These PD-associated SNPs are
not highly ranked by CADD (score < 10), however two of
them (rs356182 and rs356219) were detected by other stud-
ies as associated to PD (59,60).
As observed in previous reports (61,62), RBPs and tar-
get RNAs are expressed in tissue-specific patterns that are
altered in pathological conditions. Thus, it is possible that
SNPs in TIAR and ELAVL1 loci affect their RBP activ-
ities modifying SNCA expression. To test this hypothe-
sis, we computed trans expression Quantitative Trait Loci
(trans-eQTLs) of TIAR and ELAVL1 SNPs in relation to
SNCA using 10 brain tissues available fromGTEx database
(Supplementary Materials) (63). Remarkably, hippocampus
and nucleus accumbens basal ganglia showed highly sig-
nificant SNCA trans-eQTL P-values (<1.9e−4) associated
with polymorphisms in TIAR locus. The link is particularly
evident in hippocampus, where polymorphisms rs7912058,
rs113562141, rs4751739 and rs4751740 (R2 = 1; D’ = 1 be-
tween them) located few kilobases dowstream TIAR, reach
a SNCA trans-eQTL P-value of 9e−5, showing a singu-
larly strong association between the two loci (Figure 9A).
In addition, we found that the minor allele of the lead-
ing SNP rs7912058-G is associated with decreased expres-
sion of SNCA (Supplementary Figure S7). Our result is fur-
ther supported by a trans-eQTLs analysis of 22 818 tag-
SNPs from 100 randomgenes showing low interaction score
in our protein array experiments. Indeed, out of 22 818
only three tag-SNPs (rs72983079 in GNA15, rs3782119 in
BET1L and rs116911351 in C20orf166 gene) achieved sig-
nificant P-values in the order of magnitude of e−4, which
further highlights the strength of the association withTIAR
(binomial test P-value = 0.02).
The SNPs in the trans-eQTLs TIAR region (Figure 9A)
present the typical pattern of linkage disequilibrium (LD)
decay of GWAS association signals, with a dominant SNP
surrounded by variants with lower P-values. Interestingly,
using PLINK algorithm (64), we calculated that our trans-
eQTLs are in moderate LD (R2 ∼ 0.4; D’ = 1) with sig-
nificantly PD-associated SNPs in TIAR locus found in a
previous work (58) (Figure 9B). Overall, this indicates that
the association of TIAR with PD might come from its reg-
ulatory role in SNCA expression. The same genomic region
hosts cis-eQTLs for TIAR locus (rs11199019, rs185650278,
rs4636576, rs6585553, rs4752328; tibial nerve tissue) sug-
gesting that this sequence exerts a regulatory role on TIAR
gene expression.
As for the ELAVL1 gene, we could not find any signifi-
cant association with PD, nor significant trans-eQTLs for
SNCA gene.
DISCUSSION
In the last twenty years many efforts have been under-
taken to study the biochemical features of PD-associated
-synuclein from aggregation and post-translational mod-
ification to turnover and interaction with cellular compo-
nents (64–66). However, recent studies (5,6) revealed the im-
portance of transcriptional and post-transcriptional regula-
tions in the context of pathology (67). For the first time, we
presented here a study on the post-transcriptional regula-
tion of -synuclein by RBPs targeting the 3′ untranslated
region of its mRNA.
Using a large-scale in vitro / in silico screening, we discov-
eredRBPs interacting withSNCA 3′ UTR. Two interactors,
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pattern of linkage disequilibrium (LD) decay of association signals, with a top-associated SNP and other surrounding associated SNPs in progressively
decaying LD values (‘Recombination rate’ on right y-axes). (B) PD-associated SNPs from previous GWAS studies (58) in the genomic region of chromo-
some 10 including TIAR gene. The –log(P-value) is represented on the left y-axes, while the ‘recombination rate’ is represented on the right y-axes. The
region downstream TIAR locus where significant SNCA trans-eQTLs map is highlighted with a purple rectangle.
ELAVL1 and TIAR, bind to different SNCA isoforms gen-
erated by alternative polyadenylation mechanisms. Among
5 different known transcript isoforms, the one carrying the
short 3′UTR (575 bases) was found to be the most abun-
dant in SH-SY5Y and HeLa cells (∼50% of total SNCA
mRNA). Using a gene reporter assay, we observed that the
short 3′UTR isoform is more active than longer isoforms
(1.07 and 2.5 kb 3′UTR) and highly contributing to protein
synthesis in vivo. The short 3′UTR contains high-affinity
binding sites for both RBPs in a region comprised between
190–575 nt.
Knockdown and overexpression experiments in HeLa
cells show that ELAVL1 and TIAR positively regulate en-
dogenous -synuclein. The mechanism through which the
two RBPs regulate -synuclein expression implies mRNA
stabilization, as shown by the RNA decay assay, and en-
hancement of translation in the case of TIAR, as demon-
strated by polyribosome profiling experiments. This result
is compatible with the well-documented role of ELAVL1
as RNA stabilization factor. Indeed, ELAVL1 interferes
withARE-dependentmRNAdegradation by protecting the
body of the mRNA from decay, rather than slowing down
mRNA deadenylation (34). While it is generally assumed
that ELAVL1 stabilizes mRNAs primarily by competing
with proteins designated to mRNA degradation such as
AUF-1, KSRP or TTP (21,68,69), other mechanisms, such
a direct competition with microRNAs or regulation of mi-
croRNAs expression, might be involved (70,71). It would
be of great interest to investigate the role of microRNAs
in TIAR- and ELAVL1-dependent regulation of SNCA.
However, our analysis indicates that the level of expression
of microRNAs targeting TIAR and ELAVL1 binding sites
is poor in two independent HeLa cell lines. We therefore
excluded that microRNAs might have any relevant role in
TIAR and ELAVL1 dependent SNCA regulation in our
functional assays.
As for the effect observed on SNCA mRNA translation,
our results show that TIARpromotes protein production by
shifting SNCA mRNA towards the high molecular weight
polysomal fractions. Although TIAR was previously re-
ported as a translational inhibitor in presence of stress con-
ditions by induction of stress granules formation (72), it is
possible that it has a dual role in RNA translation. Indeed,
as described for other RBPs, many factors contribute to de-
termine the final regulatory effect on target RNAs, from the
sequence and structure of binding regions to the availability
of interacting partners (18). Further characterization of the
molecular complexes formed by TIAR and ELAVL1will be
needed to elucidate the mechanism of regulation of SNCA.
Notably, TIAR, together with other RBPs markers of stress
granules, was found in pathological lesions of several neuro-
logical conditions, such as Alzheimer disease, prion disease,
tauopathies and Huntington disease (73–76). This observa-
tion suggests that the aberrant assembly of ribonucleopro-
tein granules could alter the expression of a number of tar-
get genes leading to toxicity (77).
Interestingly, TIAR and ELAVL1 protein levels are al-
tered in post-mortem brain tissues from patients affected by
PD andMSA. In correlation with -synuclein levels, we ob-
served a down-regulation of TIAR in PD and an increase of
ELAVL1 in MSA. This result suggests that the two RBPs
have a key role in PD and MSA. Indeed, ELAVL1 was re-
cently shown to play a neuroprotective role in mice hip-
pocampal neurons following strong glutamatergic excita-
tion through the post-transcriptional orchestration of spe-
cialized genes involved in mitochondrial dysfunction, ox-
idative damage and programmed cell death (78). Similarly,
TIAR was found to target a number of genes associated
with inflammation and mitochondrial metabolism, such as
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TNF-alpha, COX-2 and mitochondrial cytochrome C (79–
81). In agreement with these observations, a previous study
reported significant increase in the level of innate immune
components including complement and cytokines (e.g., IL-
1, IL-2, IL-6 and TNF) in the substantia nigra and CSF
of PD patients (82). Moreover, microglial activation was
reported to parallel neuronal degeneration in MSA (83)
and increased expression of proinflammatory genes was ob-
served in post-mortem tissue from the rostral pons of MSA
patients (84). Supporting these findings, polymorphisms in
proinflammatory genes such as IL-1, IL-1 or TNF-
were reported to be associated with increased MSA risk
(85,86). Therefore, we speculate that the two RBPs might
coordinately regulate the expression of entire sets of genes
involved in pathways characteristics of PD and MSA neu-
rodegeneration.
Notably, TIAR and ELAVL1 were identified in a group
of 2000 significantly down-regulated genes in a network-
basedmeta-analysis of four independent microarray studies
sporadic and LRRK2-associated PD cases (16). Additional
indications of TIAR association to PD via regulation of -
synuclein, come from the GWAS and trans-eQTLs analy-
sis on the genomic locus comprising TIAR region. Impor-
tantly, Nalls et al. (58) found a group of frequent variants
in TIAR locus with significant association to PD. This find-
ing is in strong agreement with our trans-eQTLs analysis
that identifies a group of SNPs in the same genomic locus
influencing SNCA expression in two different brain areas,
nucleus accumbens and hippocampus.
Fundamental questions about the mechanism through
which TIAR- and ELAVL1-mediated regulation of SNCA
can lead to disease remain to be addressed. To what extent
-synuclein overexpression caused by the increase of TIAR
and ELAVL1 activity can induce protein aggregation and
cell toxicity? Is -synuclein the only PD-associated target
of these two RBPs?
From a more clinical perspective, testing TIAR and
ELAVL1 levels in human biospecimen (urine, blood, serum
or cerebrospinal fluid) would be of great interest for im-
proving the diagnosis and prognosis of different synu-
cleinopathies. Indeed, distinguishing MSA from PD can
be difficult owing to PD-like features in MSA, includ-
ing occasionally a transient L-dopa response in some pa-
tients. Moreover, MSA is characterized by a prognosis of a
markedly shorten life span with respect to PD (87,88), so a
high level of accuracy in the diagnosis is needed but not yet
available (89).
In conclusion, further studies would be needed to obtain
deeper insights into the role of TIAR and ELAVL1 in the
development of PD and other synucleinopathies, which will
help to evaluate the impact of post-transcriptional events
on disease.
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